Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) Stock Position Increased by Tealwood Asset Management Inc.

Tealwood Asset Management Inc. boosted its position in Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) by 50.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 15,000 shares of the medical equipment provider’s stock after purchasing an additional 5,000 shares during the quarter. Tealwood Asset Management Inc.’s holdings in Corindus Vascular Robotics were worth $45,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Hudson Executive Capital LP raised its position in shares of Corindus Vascular Robotics by 25.6% during the 1st quarter. Hudson Executive Capital LP now owns 14,235,545 shares of the medical equipment provider’s stock worth $24,770,000 after buying an additional 2,899,391 shares in the last quarter. EAM Global Investors LLC bought a new stake in shares of Corindus Vascular Robotics during the 1st quarter worth about $1,024,000. Virtu Financial LLC raised its holdings in shares of Corindus Vascular Robotics by 128.4% in the 1st quarter. Virtu Financial LLC now owns 173,312 shares of the medical equipment provider’s stock worth $301,000 after purchasing an additional 97,445 shares in the last quarter. Freestone Capital Holdings LLC bought a new stake in shares of Corindus Vascular Robotics in the 2nd quarter worth approximately $251,000. Finally, First Republic Investment Management Inc. bought a new stake in shares of Corindus Vascular Robotics in the 1st quarter worth approximately $122,000.

Shares of NYSEAMERICAN CVRS traded up $0.01 during midday trading on Friday, reaching $4.27. The company’s stock had a trading volume of 9,800 shares, compared to its average volume of 2,063,639. Corindus Vascular Robotics Inc has a one year low of $0.78 and a one year high of $4.30.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last released its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $4.58 million for the quarter, compared to analyst estimates of $4.10 million.

A number of analysts recently commented on CVRS shares. Zacks Investment Research downgraded shares of Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a report on Tuesday, August 13th. Cowen downgraded shares of Corindus Vascular Robotics from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $4.00 to $4.28 in a report on Thursday, August 8th.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for coronary and peripheral interventional procedures.

Featured Article: What are trading strategies for the 52-week high/low?

Want to see what other hedge funds are holding CVRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS).

Institutional Ownership by Quarter for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.